To determine the pattern of genetic alterations in primary central nervous system lymphomas (PCNSL), 19 PCNSL were studied by high-density single-nucleotide polymorphism arrays. Recurrent losses involved 6p21.32, 6q21, 8q12-12.2, 9p21.3, 3p14.2, 4q35.2, 10q23.21 and 12p13.2, whereas gains involved 18q21-23, 19q13.31, 19q13.43 and the entire chromosomes X and 12. Partial uniparental disomies (pUPDs) were identified in 6p and 9p21.3. These genomic alterations affected the HLA locus, the CDKN2A/p16, CDKN2B/p15 and MTAP, as well as the PRDM1, FAS, MALT1, and BCL2 genes. Increased methylation values of the CDKN2A/p16 promoter region were detected in 75% (6/8) PCNSL. Gene expression profiling showed 4/21 (20%) minimal common regions of imbalances to be associated with a differential mRNA expression affecting the FAS, STAT6, CD27, ARHGEF6 and SEPT6 genes. Collectively, this study unraveled novel genomic imbalances and pUPD with a high resolution in PCNSL and identified target genes of potential relevance in the pathogenesis of this lymphoma entity.
Introduction
Primary central nervous system lymphomas (PCNSL) are aggressive B-cell lymphomas confined to the central nervous system associated with a poor prognosis. 1, 2 They are classified as diffuse large B-cell lymphoma (DLBCL). 3, 4 However, it is still a matter of debate whether they differ from systemic DLBCL with respect to their molecular features and pathogenesis.
Studies addressing the genetic characteristics of PCNSL identified recurrent chromosomal abnormalities. [5] [6] [7] In addition to translocations of the immunoglobulin (IG) and the BCL6 loci present in a subset of PCNSL, gains and losses of genetic material are recurrent in PCNSL. 8, 9 Gains of 18q were the most frequent alteration (38%) in one series of 13 PCNSL analyzed by interphase fluorescence in situ hybridization (FISH). 5 High-level amplifications were mapped to 18q21-23 by comparative genomic hybridization to chromosomes in two tumors of a series of 19 PCNSL. 7 In addition, gains of 12q (63%, 12/19), 1q, 9q, 16p, and 17q (26% each, 5/19) were identified by comparative genomic hybridization and/or FISH. 7 Furthermore, deletion of 6q was reported in 47% (9/19) PCNSL. 7 Finally, deletion of the human leukocyte antigen (HLA) class II region in 6p21.32 including homozygous loss was reported to affect more than half of all PCNSL and to be associated with loss of MHC expression. [10] [11] [12] Although these studies provided interesting and important insights into the genetic abnormalities in PCNSL, they were limited by a low resolution and the inability to detect partial uniparental disomy (pUPD). Therefore, a series of 19 PCNSL was studied by high-density single-nucleotide polymorphism (SNP) arrays. This high-resolution technology allowed narrowing down chromosomal regions of interest and, furthermore, identification of novel imbalances and regions with pUPD.
Materials and methods

Clinical data
Stereotactic biopsies of 19 immunocompetent patients (11 females and 8 males) were included in this study. All studies were approved by local ethics committees. Informed consent was provided according to the Declaration of Helsinki Principles. Systemic lymphoma manifestation was excluded by extensive staging. All PCNSL were histopathologically classified as CD20 þ DLBCL according to the World Health Organization (WHO) classification. 3 The diagnoses were based on a combination of routine morphology and immunohistochemistry using monoclonal mouse antibodies against CD20, CD45, Ki-67 (MIB-1), IgM, IgG, BCL6, and MUM1/IRF4 as reported earlier. 13, 14 The clinical characteristics are summarized in Table 1 .
GeneChip 100k mapping array
DNA extraction was carried out as reported previously. 15 For each tumor sample, a total of 500 ng DNA were processed according to the Affymetrix GeneChip Mapping 100k Assay Manual (Affymetrix, Santa Clara, CA, USA). Briefly, 250 ng of genomic DNA was digested with XbaI or HindIII and ligated to GeneChip Human Mapping 50k adaptors. Adaptor-ligated restriction fragments were amplified by PCR, purified, fragmented and labeled as described. 16 Samples were hybridized to GeneChip Human Mapping 50k Xba240 or Hind240 arrays (Affymetrix) using the Affymetrix Hybridization Oven 640 (Affymetrix) . Washes and staining of the arrays were performed with an Affymetrix Fluidics Station 450 (Affymetrix) , and images were obtained using an Affymetrix GeneChip Scanner 3000 (Affymetrix).
Data analysis
Reference samples: As reference, 90 HapMap samples (30 Centre d'Etude du Polymorphism Humain (CEPH) trios) provided by Affymetrix were used (http://www.affymetrix.com/ support/technical/sample_data/hapmap_trio_data.affx). The reference set was completed by a set of seven samples with diploid karyotypes hybridized in the same laboratory as the tumor samples.
Genotyping: The Bayesian robust linear model with Mahalanobis distance classifier (BRLMM) algorithm 17 was used with default parameters (score threshold ¼ 0.5, prior size ¼ 10 000, and dynamic model (DM) threshold ¼ 0.17) to genotype tumor samples together with euploid reference arrays.
Copy number analysis: Copy number was analyzed using the CNAG program v2.0 using the optimized reference selection method implemented in CNAG. 18 Thus, CNAG selected a gender-specific reference set out of the 97 controls individually for each array. Xba240 and Hind240 arrays were combined for the analysis. Segmentation of raw copy number data was carried out using the Hidden Markov Model (HMM) approach provided by CNAG. HMM parameters were adjusted individually for each array because of the differences in hybridization quality and tumor cell content (at least 80% as assured morphologically). Starting with default parameters, the mean levels of HMM states were manually adjusted to optimize segmentation results for each sample.
With regard to outliers and technical artifacts, HMM segments with aberrant copy number were considered as copy number aberration only if they consisted of at least 10 consecutive SNPs. The given breakpoints refer to the first neighboring SNPs without alteration. Homozygous deletions were defined as aberrations with copy number ¼ 0. Aberrant regions were compared to the published data of the 'Database of Genomic variants.' 19 Regions showing overlap 450% with known genomic variants were classified as copy number polymorphisms (CNV).
Detection of loss of heterozygosity/pUPD: The HMM-based method 20 implemented in the dChip program (build date: 11
April 2007) 21, 22 was used to infer regions with loss of heterozygosity (LOH). The HMM considering haplotype (linkage disequilibrium (LD)-HMM) 20 method was selected for the LOH calculations to account for LD-induced SNP dependencies. The LOH call threshold was set to the default value of 0.5. An empirical haplotype 20 correction was applied. Thus, the genotypes of putative tumor LOH regions were compared with those observed in euploid reference samples. If the genotypes in the respective region were highly concordant between the tumor sample and at least 5% of the normal reference samples, the LOH region was rejected by dChip.
pUPD regions represent genomic regions in which LOH is not caused by altered copy number. LOH regions determined by dChip were called pUPD if copy number analysis using CNAG did not show aberrations within that region. If an LOH region was partially affected by copy number aberrations, subregions with normal copy number were called pUPD if they comprised at least 50 neighboring SNPs.
Correlation of minimal common regions with gene expression profiles
For all PCNSL (i.e., case nos. 1-18), except for PCNSL 19, gene expression profiles were available (GEO database 23 
GSE6047
24 ). For all mRNAs in the minimal common regions (MCR) detected by SNP, corresponding tags on the HG-U95Av2 platform (Affymetrix) were evaluated for mRNA expression. Normalized gene expression profiles 24 were analyzed in geWorkbench (http://wiki.c2b2.columbia.edu/workbench/index.php/Home). After replacing all values below 100 by 100 (background noise correction) and log2 transformation, mRNAs of tumors harboring these MCRs were compared with those without genetic alterations in these loci as evidenced by SNP analysis. Statistically significant differential expression was determined using Student's t-test with a-correction. Abbreviations: ABC, GCB, 'type 3', activated B-cell-like, germinal center B-cell-like and 'type 3' (non-ABC/non-GCB) of DLBCL classified by gene expression profiling; DLBCL, diffuse large B-cell lymphoma; F, female; M, male; MCR, minimal common region, note that only regions with alterations in more than 20% are assigned as described in Table 2 ; NA, not analyzed; PCNSL, primary central nervous system lymphoma; pUPD, partial uniparental disomy.
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Sequencing of the PRDM1 gene
Sequencing of the PRDM1 gene was carried out as described previously. 25 In brief, all exons of the PRDM1 gene were amplified by PCR. Amplicons were separated by agarose gel electrophoresis, subsequently cleaned up and directly sequenced from both sides.
FISH
To verify copy number results from 100k GeneChip analyses, dual-color FISH was applied. FISH probes consisted of spectrum orange (so) or spectrum green (sg) (Abbott/Vysis, Downers Grove, IL, USA) labeled P1-derived or bacterial artificial chromosome (PAC/BAC) clones (Invitrogen, Karlsruhe, Germany). The clones RP1-93N13 (so) and RP1-172K2 (sg) 12 were used to detect deletions in the HLA region in 6p21.32, and clones RP11-140A9 (sg) and RP11-1081N13 (so) to detect deletions in 8q12. In addition, two commercial assays were applied to confirm copy number changes of MALT1 and ETV6 (LSI MALT1 and LSI ETV6 dual-color break apart probes, Abbott/ Vysis). Probe preparation and FISH were performed as published. 26 Whenever possible, at least 100 interphase nuclei were evaluated per hybridization.
Bisulfite pyrosequencing
Bisulfite pyrosequencing of CDKN2A/p16 was performed according to standard protocols with slight modifications in eight PCNSL (case nos. 02, 03, 06, 10, 11, 14, 17 and 19) , in which sufficient material was available. 27 Briefly, genomic DNA was bisulfite converted using the EpiTect Bisulfite Conversion Kit (Qiagen, Hilden, Germany). In a subsequent PCR amplification, locus-specific primers were used with one primer 
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. Amplification reactions contained B75 ng bisulfite-converted DNA, primers, AccuPrime Taq Polymerase and buffer II (Invitrogen, Karlsruhe, Germany), 50 mM MgCl 2 and 5 mM of each dNTP in a final volume of 50 ml. After initial denaturation, PCR consisted of 45 cycles of each 95 1C for 30 s, 60 1C for 30 s and 68 1C for 30 s, followed by a final synthesis at 68 1C for 2 min. PCR products were verified by gel electrophoresis. Single strands were prepared using the VacuumPrep Tool (Biotage, Uppsala, Sweden), followed by a denaturation step at 85 1C for 2 min and final sequencing primer (5 0 -CCCTCTACCCACCTAAAT-3 0 ) hybridization. Pyrosequencing was performed using the Pyrosequencer ID and the DNA methylation analysis software Pyro Q-CpG 1.0.9 (Biotage), which was also used to quantify the ratio T:C (mC:C) at the CpG sites analyzed. Assays were validated using an in vitro methylated DNA (Millipore, Billerica, MA, USA) and pooled DNA was isolated from 20 peripheral blood samples from 10 men and 10 women. The latter was also used as a normal control.
Results
Frequency of genomic imbalances and pUPD
All PCNSL harbored at least three regions of chromosomal imbalances or pUPD. The median of aberrant regions per PCNSL was 18. A genomic overview of gains and losses detected in the 19 investigated PCNSL is presented in Figure 1a . A total of 188 genomic losses (median per PCNSL: 9, range: 0-32) and 126 genomic gains (median per PCNSL: 6, range: 0-13) were identified. Overlapping genomic segments of copy number changes delineated MCRs. In each of the cases, between 0 and 12 MCRs were affected. Chromosomal regions that were affected in at least 4 (21%) PCNSL are summarized in Table 2 . Table 2 ). The 100k GeneChip data of the PCNSL were also subjected to LOH analysis in order to detect regions of pUPD. Overall, we identified 78 regions of pUPD in 17 of these PCNSL with a median number of 4 pUPDs per PCNSL (range: 0-12). The genome-wide distribution of pUPD is shown in Figure 1b .
Loss of genetic material and pUPD
The region most commonly affected by loss or pUPD (14/19, 74%) was located in 6p21.32 ( Figure 2a , Table 2 , MCR 5). In two of these PCNSL (case nos. 04 and 05), homozygous loss was detected and subsequently confirmed by FISH. The MCR comprised 0.3 Mb and harbored the MHC class II encoding genes HLA-DRB, HLA-DQA, and HLA-DQB. Remarkably, the region most commonly affected by pUPD extended from the HLA region to the telomeric region of 6p. Of the 19 PCNSL, 10 (53%) harbored a deletion in the long arm of chromosome 6 with an MCR of 2.0 Mb in 6q21 ( Figure 2a , Table 2 , MCR 6). The MCR encompassed 11 genes, among them the PRDM1 gene. In this region, a pUPD was not detected. Sequencing of all exons of the PRDM1 gene failed to detect any mutations of the second allele in the tumors with heterozygous deletion of PRDM1. Table 2 , MCR 9). In five of these cases, heterozygous deletion was confirmed by FISH. Six (32%) PCNSL showed a small (1.0 Mb) MCR of a deletion in 9p21.3 involving CDKN2A/p16, CDKN2B/p15, and MTAP ( Figure 2b , Table 2 , MCR 11). In one of these PCNSL, the deletion was homozygous. Further three PCNSL showed a pUPD in this region.
A small minimally deleted region affecting only one SNP within the 3p14.2 region was detected in 4 (21%) PCNSL, encompassing the FHIT gene locus (Figure 3a , Table 2 Table 2 , MCR 15), were observed in four (4/19, 21%) PCNSL. One PCNSL harboring a 12p13.2 deletion (PCNSL no. 13) even showed a homozygous loss, which was confirmed by FISH.
Gains of genetic material
Chromosomal gains affected regions ranging in size from 84 kb to whole chromosomes. Eight (43%) PCNSL showed a gain in 18q21.1-q23. In seven of these cases both MALT1 and BCL2 
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were affected, whereas in a single case only the BCL2 gene was gained ( Figure 3g , Table 2 Table 2 ). Four of 19 (21%) PCNSL showed gains in 7q21.3-q22.1 (Figure 3c , MCR 7, Table 2 ). Four additional tumors harbored gains in 9p13.3 (Table 2) , the latter containing the NFX1 and BAG1 genes ( Figure 2b , MCR 12).
Comparison of MCR with gene expression profiles
To investigate the effect of chromosomal imbalances on expression of genes within the MCR, corresponding tags on the HG-U95Av2 platform were further studied ( Table 2) . 24 In 17 of 21 MCRs, at least one mRNA could be analyzed with respect to a differential expression between PCNSL with and without any alteration in the respective MCR. Only four MCRs showed a differential expression of at least one mRNA.
In MCR 13 (loss of 10q23.21), only one of seven mRNA was significantly differentially expressed (P ¼ 1.9EÀ03). As depicted in Supplementary Figure 1 , FAS expression was very low in cases with alterations in this MCR but also in 5 of 14 PCNSL without alterations in MCR 13.
For MCR 14 (gain of chromosome 12), 668 tags were analyzed; of these, 203 of these tags were differentially expressed, whereas expression of 186 tags (92%) was below 100, that is, the defined background threshold. Seventeen tags, corresponding to 16 genes, were significantly differentially expressed at higher levels, including STAT6 and CD27 (Supplementary Figure 1) .
In MCR 19 (gain of chromosome 19q13.31), one tag, corresponding to the gene ETHE1, was significantly differentially expressed (P ¼ 9.8EÀ03, Supplementary Figure 1) .
In MCR 21 (gain of chromosome Xq21.33-q28), 87 of 217 tags showed a significantly differential expression. Expression values were below 100, that is, the defined background threshold, in 83 of 87 (95%) of these tags. The four tags with a differential expression corresponded to two genes, ARHGEF6 and SEPT6 (Supplementary Figure 1) .
Methylation status of the CDKN2A/p16 locus in PCNSL As shown in Figure 4 , six of eight PCNSL showed increased methylation at the CDKN2A/p16 locus compared with controls. Methylation in PCNSL with heterozygous deletion at the CDKN2A/p16 locus was increased as compared with PCNSL without deletion in 9p, although this did not reach significance owing to the limited number of samples in each group. Thus, both deletions and DNA methylation may be considered as mechanisms of CDKN2A/p16 inactivation in PCNSL.
Discussion
In this study, genomic imbalances and LOH were addressed in a series of 19 PCNSL using high-density oligonucleotide arrays. PCNSL showed multiple chromosomal imbalances. In addition to novel recurrent regions of genomic imbalances, unknown regions of pUPD were identified, and homozygous and heterozygous deletions in PCNSL involving the HLA locus and the tumor suppressor gene loci MTAP, CDKN2A/p16, and CDKN2B/p15 were confirmed.
Alterations in 6p21.32 by deletion or pUPD were the most frequent abnormality (14/19, 73%). The altered region harbors the HLA-DRB, HLA-DQA, and HLA-DQB genes. These findings are in line with previous reports on homozygous and heterozygous deletions at the HLA class II locus, which were associated with a lack of MHC class II antigen expression by the tumor cells of PCNSL. The progressive loss of MHC proteins may facilitate tumor cell escape from the immune response. 11, 12, 28 This may be particularly relevant for lymphomas of immunoprivileged organs such as brain and testis, which are characterized by a physiologically downregulated immunophenotype, including low numbers of lymphocytes. In fact, in extracerebral DLBCL, decreased CD8 T-cell numbers have been noticed in MHC class II-negative as compared with MHC class II-positive tumors (median: 2.8 vs 11%), and MHC class II-negative DLBCL were correlated with a poor outcome. 29, 30 Ten (53%) PCNSL showed a deletion involving 6q21, being in accordance with data reported previously. 7, 10 The chromosomal region 6q21 is frequently deleted in various B-cell malignancies, including DLBCL, mantle cell lymphoma, acute lymphatic leukemia and immunoblastic lymphoma. 7, [31] [32] [33] [34] [35] This region has been suggested to harbor a tumor suppressor gene. In fact, 6q21 contains the PRDM1 gene encoding BLIMP1, which has recently been reported to function as tumor suppressor gene in PCNSL as well as in systemic DLBCL of the activated B-cell type. 25, 34, 36 In a significant fraction (4/21, 21%) of PCNSL, inactivating mutations of the PRDM1 gene were associated with loss of BLIMP1 protein expression. 25 These mutations may contribute to tumorigenesis by blocking terminal B-cell differentiation. In this context, it is of note that the tumor cells of PCNSL are impaired in their differentiation as they do not perform Ig class switch recombination and, thus, are characterized by an IgM þ IgD þ phenotype. 37 However, in this study, sequencing analysis of 8 of the 10 identified PCNSL with 6q21 deletion failed to detect any PRDM1 mutation, which could suggest that either biallelic BLIMP1 inactivation is a secondary event in PCNSL or that alternative means of BLIMP1 inactivation exist in PCNSL.
SNP chip analysis also showed heterozygous deletions in 8q with a 2.4-Mb MCR between 8q12.1 and 8q12.2 in 6 of 19 (32%) PCNSL. This MCR harbors a gene encoding the nuclear factor TOX (KIAA0808), which is required for CD4 T-cell development. 38 Is it interesting that the IgG þ B-cell population was reduced in the spleen of TOX-deficient mice. However, early steps of B-cell development apparently were normal in these animals. It is intriguing to speculate that TOX may contribute to the observed arrest of B-cell differentiation in PCNSL. TOX has been reported to be also deleted in 4% (8/205) of childhood acute lymphatic leukemia. 39 Further candidate genes within the 8q12.1-8q12.2 region are the potential oncogene CA8, which promotes growth, proliferation and invasion of carcinoma cells, [40] [41] [42] and the RAB2A gene encoding the ras-related rab2.
The tumor suppressor genes, CDKN2A/p16 and CDKN2B/ p15, at 9p21.3 as well as MTAP were targeted by recurrent deletions and pUPD present in 6 and 3 of 19 (32 and 16%) PCNSL, respectively. One PCNSL even showed a biallelic loss. 43 Furthermore, CDKN2A/p16 has been shown to be methylated in 64% (16/25) in PCNSL. 44 P16, that is, one of the encoded proteins, specifically inhibits CDK4 and CDK6 and potentially blocks G1 cell-cycle progression through the dephosphorylation of retinoblastoma through its inhibitory effect on the CDK4/cyclin D1 complex activity. 45 Compared with previous studies, in which DNA methylation of the CDKN2A/ p16 locus in PCNSL was mostly analyzed by methylationspecific PCR, we accurately quantitated methylation of 13 CpG dinucleotides by bisulfite pyrosequencing of DNA from eight PCNSL of this series. Our identification of recurrent CDKN2A/ p16 promoter methylation, which likely leads to its invactivation, is in accordance with Chu et al. 44 Moreover, the frequent methylation of the gene in PCNSL with heterozygous deletions suggests that biallelic inactivation in these tumors may result from two different mechanisms, that is DNA methylation and chromosomal deletion.
Additional recurrent deletions present in at least 4 (21%) PCNSL were in 3p14.2, 4q12, 4q13.1, 4q35.2, 10q23.21, and 12p13.2. In 3p14.2, the FHIT gene was partially deleted. FHIT, which is supposed to have a key function in tumor suppression, 46, 47 has been shown to be either deleted or mutated in 33% (19/57) of systemic DLBCL. Clinically relevant, decreased FHIT expression has been reported to correlate with an inferior prognosis in systemic DLBCLs. 48 In 4q12, a 200-kb MCR of deletion involving the SCFD2 gene, a potential p53 target gene, was detected. 49 In 4q35.2, the FAT tumor suppressor gene was affected by deletion. Another small MCR of deletion affected the tumor suppressor gene FAS gene at 10q23. 21 . FAS (CD95), a transmembrane receptor of the tumor necrosis factor superfamily, is an important mediator of apoptosis. 50 FAS mutations, which may impair apoptosis, have been identified in 20% (2/10) PCNSL. 15 In 12p13.2, a 200-kb MCR of deletion was detected with one PCNSL showing biallelic loss; in another PCNSL, the pattern of imbalances suggested a deletion to have occurred before amplification of an allele. The deletions affected the ETV6 gene, which is frequently translocated in hematopoietic tumors. 51 In PCNSL, recurrent gains in 18q have been described by various groups. 1, [5] [6] [7] 10 18q21 harbors the BCL2 and MALT1 genes. MALT1 complexes with BCL10 and a CARD protein to activate the nuclear factor-kB pathway. 52 In fact, both MALT1 and BCL10 are expressed by the tumor cells of PCNSL, which also show evidence for an activation of the nuclear factor-kB pathway. 53 In our study, 8/19 PCNSL and 7/19 PCNSL showed gains of BCL2 and MALT1, respectively. Microarray data identified two small MCRs frequently gained in 19q13.31 and 19q13.43. Both regions harbor several genes encoding zinc finger proteins, which might be involved in transcriptional regulation. This region partly overlaps with a region of gain in 19q13.12-13.43 detected in 2 (22%) PCNSL recently. 10 In accordance with previous observations, [5] [6] [7] two PCNSL showed gains of 12p11.21-q24.33 and 12q24.11-12q24.33, and five further tumors showed triploidy of chromosome 12. Furthermore, PCNSL had two small MCRs of copy number gains in 7q21.3-q22.1 and 9p21.1-p21.3 and one large MCR of recurrent copy number gain in Xq21.33-q28. The region 7q21.3-q22.1 harbors the candidate genes NFX1 and BAG1. NFX1 is a nuclear transcription factor, which downregulates HLA class II antigen expression. 54 Bag1 interacts with Bcl2 to increase its antiapoptoic activity. 55 It is tempting to speculate that PCNSL corresponding to the ABC and GCB subgroups as defined for systemic [56] [57] [58] may be characterized by different patterns of genomic aberrations indicating particular and distinct pathways relevant for pathogenesis. In this series of PCNSL, MCR 2 (loss 4q12), MCR 3 (loss 4q13.1), and MCR 15 (loss 12p13.2) were exclusively associated with the ABC-type, whereas MCR 14 (gain chromosome 12) was only observed in the GCB-subtype of PCNSL. However, this observation should be interpreted with caution due to the low number of PCNSL available for such studies, which precludes such an analysis.
In conclusion, the identification of novel candidate tumor suppressor genes and oncogene loci through high-density oligonucleotide SNP array analysis may provide the basis for further studies aiming at the identification of genes involved in PCNSL tumorigenesis.
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